A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma

NRAS mutations are the most common alterations among RAS isoforms in cutaneous melanoma, with patients harboring these aggressive tumors having a poor prognosis and low survival rate. The main line of treatment for these patients is MAPK pathway‐targeted therapies, such as MEK inhibitors, but, unfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagler, Adi, Vredevoogd, David W., Alon, Michal, Cheng, Phil F., Trabish, Sophie, Kalaora, Shelly, Arafeh, Rand, Goldin, Victoria, Levesque, Mitchell P., Peeper, Daniel S., Samuels, Yardena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383499/
https://www.ncbi.nlm.nih.gov/pubmed/31549767
http://dx.doi.org/10.1111/pcmr.12825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383499/
https://www.ncbi.nlm.nih.gov/pubmed/31549767
http://dx.doi.org/10.1111/pcmr.12825

Ejemplares similares